NeuroSense Therapeutics Financial Report for Fiscal Year GAAP EPS

Monday, 8 April 2024, 05:22
The recent financial report from NeuroSense Therapeutics for fiscal year ending shows a GAAP EPS of -$0.83, slightly missing expectations by $0.01. As of December 31, 2023, the company held approximately $2.6 million in cash reserves, indicating its current financial position amidst ongoing developments.
LivaRava Finance Meta Image
NeuroSense Therapeutics Financial Report for Fiscal Year GAAP EPS

NeuroSense Therapeutics Financial Report Analysis

NeuroSense Therapeutics press release (NRSN) reveals a FY GAAP EPS of -$0.83, missing by $0.01. The company ended the year with cash reserves of approximately $2.6 million.

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe